Wang Yu-Hung, Yao Chi-Yuan, Lin Chien-Chin, Gurashi Kristian, Amaral Fabio M R, Bossenbroek Hasse, Jerez Andres, Somervaille Tim C P, Binder Moritz, Patnaik Mrinal M, Hou Hsin-An, Chou Wen-Chien, Batta Kiran, Wiseman Daniel H, Tien Hwei-Fang
Division of Cancer Sciences, The University of Manchester, Manchester, UK.
Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
Br J Haematol. 2023 Apr;201(2):302-307. doi: 10.1111/bjh.18681. Epub 2023 Feb 6.
Leukaemic stem cell (LSC) gene expression has recently been linked to prognosis in patients with acute myeloid leukaemia (17-gene LSC score, LSC-17) and myelodysplastic syndromes. Although chronic myelomonocytic leukaemia (CMML) is regarded as a stem cell disorder, the clinical and biological impact of LSCs on CMML patients remains elusive. Making use of multiple independent validation cohorts, we here describe a concise three-gene expression signature (LSC-3, derived from the LSC-17 score) as an independent and robust prognostic factor for leukaemia-free and overall survival in CMML. We propose that LSC-3 could be used to supplement existing risk stratification systems, to improve prognostic performance and guide management decisions.
白血病干细胞（LSC）基因表达最近已与急性髓系白血病患者的预后（17基因LSC评分，LSC-17）以及骨髓增生异常综合征相关联。尽管慢性粒单核细胞白血病（CMML）被视为一种干细胞疾病，但LSC对CMML患者的临床和生物学影响仍不明确。利用多个独立验证队列，我们在此描述了一个简洁的三基因表达特征（LSC-3，源自LSC-17评分），作为CMML患者无白血病生存和总生存的独立且可靠的预后因素。我们建议LSC-3可用于补充现有的风险分层系统，以改善预后评估性能并指导治疗决策。
